Paysign Q4 revenue beats estimates on strength in pharma program

Overview

• U.S. patient affordability platform's Q4 revenue rose 46%, beating analyst expectations

• Q4 adjusted EBITDA beat analyst estimates

• Company's Q4 net income was almost flat yr/yr

Outlook

• Paysign expects 2026 revenue of $106.5 mln to $110.5 mln, up 30%-35% year-over-year

• Company sees 2026 net income nearly doubling to $13 mln-$16 mln, or $0.21-$0.26 per diluted share

• Paysign expects Q1 2026 revenue of $27 mln to $27.5 mln, with margin expansion versus Q1 2025

Result Drivers

• PHARMA PROGRAM GROWTH - Addition of 55 net patient affordability programs during 2025 and increased claim volume drove pharma revenue up 122% yr/yr in Q4

• PLASMA CENTER EXPANSION - Plasma revenue rose 17% yr/yr in Q4

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the business support services peer group is "buy"

• Wall Street's median 12-month price target for Paysign Inc is $9.00, about 169.5% above its March 23 closing price of $3.34

• The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 30 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.